Skip to main content
Top
Published in: EJNMMI Research 1/2022

Open Access 01-12-2022 | Prostate Cancer | Original research

Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria

Authors: Daniel Koehler, Markus Sauer, Amir Karimzadeh, Ivayla Apostolova, Susanne Klutmann, Gerhard Adam, Sophie Knipper, Tobias Maurer, Christoph Berliner

Published in: EJNMMI Research | Issue 1/2022

Login to get access

Abstract

Background

PSMA PET/CT is the recommended imaging test in cases with prostate-specific antigen (PSA) recurrence after primary therapy of prostate cancer (PCa). However, imaging protocols remain a topic of active research. The aim of the presented study was to examine the impact of additional late scans of the pelvis in [68 Ga]Ga-PSMA-I&T PET/CT of patients with rising PSA after prostatectomy.

Methods

A total of 297 patients (median PSA 0.35 ng/ml, interquartile range (IQR) 0.2–0.8) who underwent early whole-body [68 Ga]Ga-PSMA-I&T PET/CT (median dose 141 MBq, IQR 120–163; median 86 min, IQR 56–107) and additional late scans of the pelvis (median 180 min, IQR 170–191) were investigated retrospectively. Early and late images were staged separately according to the PROMISE criteria and compared with a final consensus of both. Standardized uptake values were analyzed for early and late scans.

Results

One hundred and thirty-four (45.1%) [68 Ga]Ga-PSMA-I&T PET/CT showed evidence of recurrent PCa (114/38.4% early, 131/44.1% late). Of 195 lesions, 144 (73.8%) were identified correctly on early scans. 191 (97.9%) lesions were detected on late imaging. The lesion SUVmax (median 3.4, IQR 0.4–6.5 vs. median 3.9, IQR 2.6–8.2) as well as the SUVmax to background ratio (median 9.4, IQR 1.7–19.1 vs. median 15.5, IQR 9.6–34.1) increased significantly between the imaging time points (p < 0.01, respectively). Compared to the final consensus, the miTNM-staging of early scans changed in 58 (19.5%) cases. Of these, 31 patients (10.4%) with negative early scans (T0 N0 M0) were upstaged. Twenty-seven (9.1%) patients with PCa characteristic lesions on early imaging (> T0 N0 M0) were up- and/or downstaged. In 4 (1.3%) cases, PCa-related lesions were only detectable on early PET/CT leading to upstagings of late imaging.

Conclusions

Additional late scans of the pelvis in [68 Ga]Ga-PSMA-I&T PET/CT detected more lesions and an increasing contrast compared to early imaging. This influenced the final miTNM-staging substantially.
Appendix
Available only for authorised users
Literature
2.
go back to reference Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, et al. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate. 2018;78(9):676–81.CrossRef Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, et al. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate. 2018;78(9):676–81.CrossRef
3.
go back to reference Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25(13):1765–71.CrossRef Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25(13):1765–71.CrossRef
4.
go back to reference Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4.CrossRef Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–4.CrossRef
5.
go back to reference Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.CrossRef Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.CrossRef
7.
go back to reference Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part I. J Urol. 2021;205(1):14–21.CrossRef Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part I. J Urol. 2021;205(1):14–21.CrossRef
8.
go back to reference Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793–9.CrossRef Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793–9.CrossRef
9.
go back to reference Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, et al. Impact of 68 Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59(3):434–41.CrossRef Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, et al. Impact of 68 Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59(3):434–41.CrossRef
10.
go back to reference Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956–61.CrossRef Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956–61.CrossRef
11.
go back to reference Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J Nucl Med. 2018;59(1):82–8.CrossRef Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J Nucl Med. 2018;59(1):82–8.CrossRef
12.
go back to reference Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med. 2022;63(2):240–7.CrossRef Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med. 2022;63(2):240–7.CrossRef
13.
go back to reference Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, et al. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022;49(9):3257–68.CrossRef Ceci F, Rovera G, Iorio GC, Guarneri A, Chiofalo V, Passera R, et al. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022;49(9):3257–68.CrossRef
14.
go back to reference Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.CrossRef Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014–24.CrossRef
16.
go back to reference Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44(5):765–75.CrossRef Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44(5):765–75.CrossRef
17.
go back to reference Sahlmann CO, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, et al. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(5):898–905.CrossRef Sahlmann CO, Meller B, Bouter C, Ritter CO, Ströbel P, Lotz J, et al. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(5):898–905.CrossRef
18.
go back to reference Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [68ga]ga-psma-11 pet/ct hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020;12(10):2788.CrossRef Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, et al. Dual-time point [68ga]ga-psma-11 pet/ct hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel). 2020;12(10):2788.CrossRef
19.
go back to reference Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58(5):750–5.CrossRef Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017;58(5):750–5.CrossRef
20.
go back to reference Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G, et al. Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47(1):160–7.CrossRef Alberts I, Sachpekidis C, Gourni E, Boxler S, Gross T, Thalmann G, et al. Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47(1):160–7.CrossRef
21.
go back to reference Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, et al. Combined early and late [68Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558–66.CrossRef Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, et al. Combined early and late [68Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558–66.CrossRef
23.
go back to reference Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, et al. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(6):913–22.CrossRef Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, et al. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(6):913–22.CrossRef
24.
go back to reference Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):960–8.CrossRef Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, et al. Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):960–8.CrossRef
25.
go back to reference Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM Classification for the interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59(3):469–78.CrossRef Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM Classification for the interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018;59(3):469–78.CrossRef
26.
go back to reference Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.CrossRef Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.CrossRef
29.
go back to reference Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47(3):614–23.CrossRef Alberts I, Prenosil G, Sachpekidis C, Weitzel T, Shi K, Rominger A, et al. Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison. Eur J Nucl Med Mol Imaging. 2020;47(3):614–23.CrossRef
30.
go back to reference Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, et al. 3-year freedom from progression after 68Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 2020;61(6):866–72.CrossRef Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, et al. 3-year freedom from progression after 68Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 2020;61(6):866–72.CrossRef
31.
go back to reference Knipper S, Mehdi Irai M, Rauscher I, Simon R, Eiber M, van Leeuwen FW, et al. Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery. Eur Urol. 2022;S0302–2838(22):02408–13. Knipper S, Mehdi Irai M, Rauscher I, Simon R, Eiber M, van Leeuwen FW, et al. Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery. Eur Urol. 2022;S0302–2838(22):02408–13.
32.
go back to reference Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, et al. Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis. J Nucl Med. 2019;60(2):227–33.CrossRef Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, et al. Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis. J Nucl Med. 2019;60(2):227–33.CrossRef
34.
go back to reference Alberts I, Niklas-Hünermund J, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62(9):1252–7.CrossRef Alberts I, Niklas-Hünermund J, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62(9):1252–7.CrossRef
35.
go back to reference Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohammad O, Pampaloni MH, et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2021;63(1):76–80.CrossRef Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohammad O, Pampaloni MH, et al. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2021;63(1):76–80.CrossRef
Metadata
Title
Evaluation of [68 Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria
Authors
Daniel Koehler
Markus Sauer
Amir Karimzadeh
Ivayla Apostolova
Susanne Klutmann
Gerhard Adam
Sophie Knipper
Tobias Maurer
Christoph Berliner
Publication date
01-12-2022
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2022
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-022-00938-3

Other articles of this Issue 1/2022

EJNMMI Research 1/2022 Go to the issue